Загрузка...
Effect of Anagliptin on Glycemic and Lipid Profile in Patients With Type 2 Diabetes Mellitus
BACKGROUND: Anagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor expected to improve the lipid profile as well as glycemic control. However, findings from large-scale prospective trials have not been obtained. METHODS: We performed a multicenter prospective trial in patients with type 2 diabetes...
Сохранить в:
| Опубликовано в: : | J Clin Med Res |
|---|---|
| Главные авторы: | , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Elmer Press
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6031245/ https://ncbi.nlm.nih.gov/pubmed/29977423 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14740/jocmr3464w |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|